Breaking the “Black Box” in Bioprocessing - Summary - MDSpire
Feature

Breaking the “Black Box” in Bioprocessing

Why understanding titer analytics is key to faster, more reliable biologics and gene therapy development

  • May 14, 2026

  • 10 min

Share

Ruizhi Wang, Founder and CEO of Abselion, highlights the critical role of analytics in biopharma, emphasizing the limitations of traditional techniques and the need for accessible, innovative solutions. With a background in semiconductor engineering, Wang's journey into biopharma led him to develop a solid-state measurement method that simplifies analytical workflows. The Amperion technology developed by his company supports the evolving demands of biologics and gene therapies, addressing misconceptions about titer measurements and promoting integration within the production process for improved efficiency.

Original Source(s)

Breaking the “Black Box” in Bioprocessing

  • May 14, 2026

Related Content

AI Discharge Summaries Show Low Harm Risk

Most reviewed summaries were rated as posing no harm risk, although omissions remained common.

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Uric Acid Stone Dissolution Peaked at pH 7.2

In vitro study found dissolution rates increased sharply above pH 6.5 and were tenfold higher after stone fragmentation.